ScreenerHero

PCVX Vaxcyte, Inc.

NAS · US · Healthcare · Biotechnology · vaxcyte.com
66.96USD+0.39%Mkt Cap: 9.96B $P/E: —

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-spari…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap9.96B USD
Enterprise Value8.55B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-766.63M USD
Revenue/Share—
Last Price66.96 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees507
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.86
PEG—
EV/EBITDA-7.45
EV/Revenue—
P/S—
P/B3.50
EPS (TTM)-7.62
EPS (Forward)-7.53
52W Range
31.8960% of range90.75
52W High90.75 USD
52W Low31.89 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-28.55%
ROA-25.53%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-655.58M USD
CapEx (TTM)56.97M USD
FCF Margin—
FCF Yield-4.88%
Net Debt-1.37B USD
Net Debt/EBITDA1.19
Balance Sheet
Debt/Equity0.04
Current Ratio5.72
Quick Ratio5.48
Book Value/Sh19.05 USD
Cash/Share9.99 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)108.63 USD
Upside (mean)+62.2%
Target Range67.00 USD – 163.00 USD
67.00+62.2% to mean163.00
# Analysts8
Ownership
Shares Out.148.81M
Float136.44M
Insiders0.50%
Institutions113.47%
Short Interest
Short Ratio14.6d
Short % Float10.90%
Short % Out.10.84%
Shares Short16.13M
Short (prev mo.)14.80M
Technical
SMA 5058.92 (+13.6%)
SMA 20055.29 (+21.1%)
Beta1.23
S&P 52W Chg16.45%
Avg Vol (30d)2.37M
Avg Vol (10d)2.91M
Technical Indicators
RSI (14)61.2
MACD1.6137
MACD Signal0.5022
MACD Hist.+1.1115
BB Upper68.78 USD
BB Middle59.84 USD
BB Lower50.89 USD
BB Width29.90%
ATR (14)4.672 USD
Vol Ratio (20d)4.54x